ClinicalTrials.gg
Status unknownNCT03550859Updated Dec 14, 2020

HMG-CoA Reductase add-on in Chronic Kidney Disease Patients With Proteinuria

A Phase 4 interventional study of Telmisartan/Rosuvastatin 40/10mg and Telmisartan 40mg in Chronic Kidney Disease and Proteinuria, sponsored by Yuhan Corporation. Status unknown at 16 sites in Korea, Republic of. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2020-12-14.

Sponsored by Yuhan Corporation · Phase 4, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Dec 2020), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
374
Allocation
Randomized
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 124 studies in Renal Insufficiency, Chronic with a site in Korea, Republic of — 18 open to participants now, 30 under way, 17 of them phase 3. Renal Insufficiency, Chronic · Korea, Republic of.

Planned enrollment
48th of 101
374 · median 351
Started
2018
with 8 others
Phase 4
20 of 124
none open now
Registered
60th of 124
by date

Among the 124 studies in Renal Insufficiency, Chronic with a site in Korea, Republic of, this one is the 48th largest by planned enrollment of the 101 interventional ones that give a count, is one of 9 that started in 2018, is one of 20 in phase 4, and was the 60th registered.

Renal Insufficiency, Chronic

3,096 studies on the registry are indexed under Renal Insufficiency, Chronic; 701 are open to participants now.

Browse Renal Insufficiency, Chronic studies →

Open to participants now

18 of the 124 studies in Renal Insufficiency, Chronic with a site in Korea, Republic of are open now. Recruiting first, the newest first:

13 more — sign in →

All 18 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 434 Renal Insufficiency, Chronic studies recruiting now, 244 (56%) set no upper age limit and 110 (25%) stop at 75 or younger; 44 take children under 18; 80 take healthy volunteers.

This study: 19 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 124 studies in Renal Insufficiency, Chronic with a site in Korea, Republic of, or all of them as a file.
02

Study summary

This study is to evaluate the renal function of HMG-CoA reductase add-on in chronic kidney disease patients with proteinuria.

03

Conditions studied

  • Chronic Kidney Disease
  • Proteinuria
04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Aged ≥ 19 years
  2. Chronic Kidney Disease (CKD) with CKD stage G2 or G3 and 300 mg/g ≤ urine PCR ≤ 3000 mg/g
  3. Diagnosed with hypertension
  4. Written
  5. Patients who have not administered statin (including rosuvastatin) and hyperlipidemia treatment for at least 4 weeks prior to randomization

Exclusion criteria

Exclusion Criteria:

  1. Type I diabetes
  2. Uncontrolled diabetic patients with > 10% at screening
  3. Hypertensive patients whose mean blood pressure was not controlled at 160/90 mmHg or more in triplicate despite the use of antihypertensive agents at the time of randomization
  4. Calculated LDL-C ≥ 160 mg/dL at randomization
  5. Patients who have taken RAS blockers (ACE inhibitor, ARB, and Aldosterone antagonist) for 4 weeks prior to randomization
  6. Heart failure patients with class IV
  7. Patients with acute and chronic liver disease, acute inflammation, hematologic abnormalities and cancer within the last 6 months
  8. Patients with a history of cerebral blood cardiovascular complications (cerebral infarction, , myocardial infarction, unstable angina, coronary artery bypass, and percutaneous coronary intervention)
  9. Patients taking drugs
  10. Patients undergoing \<30 mL/min/1.73 m2 (CKD-EPI formula) or renal replacement therapy (dialysis or renal transplant) at screening
  11. Patients with a change in eGFR (CKD-EPI formula) value showing a difference of more than 30% in the last 6 months at screening
  12. Creatine kinase (CK) level ≥ 3x (upper limit of normal range)
  13. Patients who are pregnant or planning to become pregnant
  14. stated in the SPC of telmisartan or rosuvastatin
  15. Those participating in other clinical trials for products at screening
  16. Patients deemed to be ineligible to participate in the trial by investigator
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
374 participants (estimated)

Study arms

  • Experimental
    Duowell Tab. 40/10mg

    Telmisartan/Rosuvastatin 40/10mg qd for 48 weeks

    Drug: Telmisartan/Rosuvastatin 40/10mg

  • Active comparator
    Micardis Tab. 40mg

    Telmisartan 40mg qd for 48 weeks

    Drug: Telmisartan 40mg

Interventions

  • DrugTelmisartan/Rosuvastatin 40/10mg

    Telmisartan/Rosuvastatin 40/10mg qd for 48 weeks

  • Telmisartan 40mg qd for 48 weeks

06

What researchers measure

Primary outcomes

  1. Rate of change from baseline to week 48 in Urine Protein to Creatinine Ratio (UPCR)

    Time frame: baseline, week 48

Secondary outcomes

  1. Change from baseline to week 24 in UPCR

    Time frame: baseline, week 24

  2. Change from baseline to week 24 and week 48 in Urine Albumin-to-Creatinine Ratio (UACR)

    Time frame: baseline, week 24, week 48

  3. Change from baseline to week 24 and week 48 in estimated glomerular filtration rate (eGFR)

    Time frame: baseline, week 24, week 48

  4. Change from baseline to week 48 in UPCR

    Time frame: baseline, week 48

  5. Change from baseline to week 48 in high-sensitivity CRP (hs-CRP)

    Time frame: baseline, week 48

  6. Change from baseline to week 48 in HOMA-insulin resistance (HOMA-IR)

    Time frame: baseline, week 48

  7. Change from baseline to week 48 in 24hr urine protein

    Time frame: baseline, week 48

  8. Proportion of subjects whose UPCR decreased by more than 30% at 48 weeks

    Time frame: baseline, week 48

  9. Change from baseline to week 48 in MCP-1 (monocyte chemoattractant protein 1)

    Time frame: baseline, week 48

  10. Change from baseline to week 48 in urinary 8-isoprostane

    Time frame: baseline, week 48

  11. Change from baseline to week 48 in urine nephrin

    Time frame: baseline, week 48

  12. Change from baseline to week 48 in type IV collagen

    Time frame: baseline, week 48

  13. Proportion of subjects who received renal replacement therapy (dialysis or renal transplant) at 12, 24, 36, or 48 weeks

    Time frame: baseline, week 12, week 24, week 36, week 48

07

Study locations

11 of 16 sites recruiting
  • Wonju Severance Christian Hospital
    Wŏnju, Gangwon-do, Korea, Republic of
    Recruiting
    • InJyung Kim · Contactnoblessik@hanmail.net · +82-33-749-0937
    • ByungGeun Han, MD PhD · Principal investigator
  • Hallym University Sacred Heart Hospital
    Anyang, Gyeonggi-do, Korea, Republic of
    Recruiting
    • SangMi Oh · Contactjinmi0320@gmail.com · +82-31-380-1770
    • Seong-Gyun Kim, MD PhD · Principal investigator
  • Seoul National University Bundang Hospital
    Seongnam, Gyeonggi-do, Korea, Republic of
    Recruiting
    • HyunJin Cho · Contact10871@snubh.org · +82-31-787-7030
    • Ki-Young Na, MD PhD · Principal investigator
  • Korea University Ansan Hospital
    Ansan, Gyeonggido, Korea, Republic of
    Recruiting
    • SangMin Lee · Contact3blue9@naver.com · +82-31-412-6764
    • DaeRyong Cha, MD PhD · Principal investigator
  • Chonbuk National University Hospital
    Jeonju, Jeollabuk-do, Korea, Republic of
    Recruiting
    • YunJeong Chae · Contactcyj70105@hanmail.net · +82-63-250-1284
    • Wok Kim, MD PhD · Principal investigator
  • Dong-A University Hospital
    Busan, Korea, Republic of
    Not yet recruiting
  • Kyungpook National University Hospital
    Daegu, Korea, Republic of
    Recruiting
    • HwaYoung Lee · Contactdlghkdud1225@naver.com · +82-53-200-6947
    • SunHee Park, MD PhD · Principal investigator
  • Chungnam National University Hospital
    Daejeon, Korea, Republic of
    Not yet recruiting
    • SeongJin Hong · Contacthsj0674@cnuh.co.kr · +82-42-280-6948
    • DaeEun Choi, MD PhD · Principal investigator
  • Inje University Ilsan Paik Hospital
    Goyang, Korea, Republic of
    Recruiting
    • HeeJaa Lee · Contactheejaalee@naver.com · +82-31-910-7776
    • Sang-Youb Han, MD PhD · Principal investigator
  • The Catholic University of Korea Incheon St.Mary's Hospital
    Incheon, Korea, Republic of
    Recruiting
    • SoonGuem Lee · Contactendo-zzang@daum.net · +82-32-280-5188
    • SeokJoon Shin, MD PhD · Principal investigator
  • Presbyterian Medical Center
    Jeonju, Korea, Republic of
    Not yet recruiting
  • Gangnam Severance Hospital
    Seoul, Korea, Republic of
    Not yet recruiting
  • Hallym University Kangnam Sacred Heart Hospital
    Seoul, Korea, Republic of
    Recruiting
  • korea Universitiy Anam Hospital
    Seoul, Korea, Republic of
    Not yet recruiting
  • KyungHee Universitiy Hospital at Gandong
    Seoul, Korea, Republic of
    Recruiting
    • JiHyun Kim · Contactcell41@naver.com · +82-2-440-7065
    • Ju Young MOON, MD PhD · Principal investigator
  • SMG-SNU Boramae Medical Center
    Seoul, Korea, Republic of
    Recruiting
    • JiYoung Kim · Contactsmile0212@daum.net · +82-2-870-3875
    • Chun Soo Lim, MD PhD · Principal investigator
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2018 (actual). Primary completion is estimated for Dec 2021, 42 months after the start.

Of 116 phase 4 interventional studies under Renal Insufficiency, Chronic, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 67. This study's planned 42 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
May 9, 2018
First posted
Jun 8, 2018
StartActual
Jun 5, 2018
Primary completionEst.
Dec 2021
CompletionEst.
Dec 2021
Last update
Dec 14, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 14, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03550859
Lead sponsor
Yuhan Corporation
Responsible party
Sponsor
First posted
Jun 8, 2018
Start date
Jun 5, 2018
Primary completion
Dec 2021 (estimated)
Completion
Dec 2021 (estimated)
Last update
Dec 14, 2020

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Dec 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion